Valiant Organics Q4 FY24 earnings call: Revenue & Margins
Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹177Cr
- +25.5% QoQ
- Net profit
- −₹20Cr
- Margin
- −1.2%
- −3 pp QoQ
Top 10 Chemicals & Petrochemicals companies on management guidance
See the sector's top 10 — free with your mobile number.
Valiant Organics Ltd Q4 FY24 key numbers
- Revenue
- Standalone Revenue from Operations for FY24: INR 6,772 million, down from INR 9,116 million in FY23.
As stated in Valiant Organics Ltd's Q4 FY24 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Valiant Organics Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year. EBITDA for Q4 FY24: INR 396 Mn (Standalone), INR 382 Mn (Consolidated); standalone EBITDA margin 5.85%, consolidated 5.28%. - Year-on-year EBITDA decline: Standalone EBITDA down from INR 1,299 Mn in FY23 to 396 Mn in FY24; margin dropped from 14.25% to 5.85%.
From Valiant Organics Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year.
- Standalone Revenue from Operations for FY24: INR 6,772 million, down from INR 9,116 million in FY23.
- EBITDA for Q4 FY24 (consolidated): INR 382 million, significantly down from INR 1,643 million in FY23.
2 more points from Valiant Organics Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ortho Amino Phenol (OAP) project:
- Status: Expected to commence soon; trial run successful but further improvement needed.
- Purpose: Currently entirely imported in India; part of production to be used for forward integration of an existing product.
- Chlorophenol capacity expansion:
- Environmental approval obtained to increase capacity to 21,600 MTPA (page 7).
- PAP factory:
- Phase 1 completed and production ramped up to over 400 MT per month; multipurpose pharma intermediates plant commenced development (page 7).
- Investment figures:
2 more points from Valiant Organics Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Valiant Organics Ltd said on order book & pipeline — free account, 30 seconds.
Valiant Organics Ltd — Quarterly revenue & net profit
Valiant Organics Ltd Q4 FY24 results — key figures
| ₹ Cr | Q4 FY24 | Q3 FY24 | QoQ |
|---|---|---|---|
| Revenue | 177 | 141 | +25.5% |
| Operating profit (EBITDA) | -2 | 3 | -166.7% |
| Operating margin | -1.2% | 1.8% | -3 pp |
| Profit before tax | -25 | -10 | — |
| Net profit (PAT) | -20 | -8 | — |
| EPS (₹) | -7.32 | -2.86 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹304 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Valiant Organics's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Gujarat Alkalies (Q4 FY24)
951.17 Crores (Page 8) . Key concall takeaways from Gujarat Alkalies & Chemicals Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Himadri Special (Q4 FY24)
1,176.95 Cr, up 14.39% YoY from Rs. Key concall takeaways from Himadri Speciality Chemical Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals (Q4 FY24)
Q4 FY24 Revenue from Operations: Rs 59.6 Cr, down 24.6% YoY from Rs 79.1 Cr in Q4 FY23 (Page 8, 6) . Key concall takeaways from Chemcon Speciality Chemicals…
- Excel Industries (Q4 FY24)
Q4 FY24 revenue: ₹233.5 Cr, a 3.3% increase quarter-on-quarter and a 29.5% increase year-on-year (Page 11, 9, 7, 5). Key concall takeaways from Excel…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Valiant Organics Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Valiant Organics Ltd Q4 FY24 results?
Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year. EBITDA for Q4 FY24: INR 396 Mn (Standalone), INR 382 Mn (Consolidated); standalone EBITDA margin 5.85%, consolidated 5.28%. - Year-on-year EBITDA decline: Standalone EBITDA down from INR 1,299 Mn in FY23 to 396 Mn in FY24; margin dropped from 14.25% to 5.85%.
What is Valiant Organics Ltd share price analysis?
Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.
Is Valiant Organics Ltd planning capital expenditure?
Ortho Amino Phenol (OAP) project: - Status: Expected to commence soon; trial run successful but further improvement needed.
Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
